Dried blood spot (DBS) testing is a minimally invasive method for detecting Alzheimer's disease pathology through capillary blood collection. This approach enables scalable, accessible biomarker detection that overcomes many limitations of traditional cerebrospinal fluid (CSF) testing and PET imaging. A landmark study published in Nature Medicine in February 2026 demonstrated the clinical utility of this approach for Alzheimer's disease detection (Huber et al., 2026; PMID:41491101). [1]
Dried blood spot testing involves pricking a finger or heel and placing blood drops onto a specialized filter paper card. The blood dries naturally and can be stored and shipped at room temperature. This method: [2]
The Nature Medicine study evaluated both dried plasma spot (DPS) and dried blood spot (DBS) approaches: [3]
The study analyzed multiple Alzheimer's disease biomarkers in dried blood samples: [4]
p-tau217 is one of the most promising blood-based biomarkers for Alzheimer's disease. [5]
GFAP is an astrocyte activation marker: [6]
NfL is a marker of neuroaxonal damage: [7]
While Aβ was analyzed primarily in CSF in this study, other research has demonstrated Aβ detection in dried blood samples.
The AT(N) classification system (Amyloid, Tau, Neurodegeneration) provides a standardized framework for understanding what DBS testing can detect. Dried blood spot testing can approximate multiple components of the AT(N) framework:
The combination of p-tau217 + GFAP + NfL in DBS format provides a near-complete AT(N) profile at a fraction of the cost of traditional biomarker testing.
| Biomarker | Sensitivity | Specificity | AUC | Correlation with Venous Plasma |
|---|---|---|---|---|
| DPS p-Tau217 | 84% | 87% | 0.864 | rS = 0.74 |
| DPS GFAP | 78% | 82% | 0.81 | rS = 0.68 |
| DBS NfL | 75% | 80% | 0.78 | rS = 0.71 |
| DBS p-Tau181 | 80% | 83% | 0.83 | rS = 0.69 |
| Disease Stage | p-Tau217 (DPS) | GFAP (DPS) | NfL (DBS) |
|---|---|---|---|
| Cognitively Normal A- | Low | Normal | Normal |
| Cognitively Normal A+ | Elevated | Elevated | Normal |
| MCI due to AD | High | High | Mildly elevated |
| AD Dementia | Highest | Highest | Elevated |
DBS testing is particularly valuable for primary care settings (Schindler et al., 2024):
DBS enables scalable population screening (Cullen et al., 2025):
The European validation study (Mattsson et al., 2023) across 12 centers demonstrated:
| Status | Biomarker | Regulatory Pathway |
|---|---|---|
| FDA Breakthrough Device | p-Tau217 (DBS) | Breakthrough device designation |
| CE-IVD Marked | DPS p-Tau181 | IVD Directive 98/79/EC |
| Research Use Only | DBS NfL, GFAP | Laboratory developed tests |
| Under Review | Multi-analyte DBS panel | FDA premarket approval |
Several companies are developing DBS-based AD biomarker tests:
| Test Type | Per-Patient Cost | Infrastructure Required |
|---|---|---|
| DBS (home collection) | $25-50 | Minimal |
| DBS (clinic collection) | $40-75 | Finger prick kit |
| Plasma (venous) | $100-150 | Phlebotomy, centrifuge |
| CSF biomarker panel | $500-1,200 | Lumbar puncture, lab |
| Amyloid PET | $3,000-5,000 | PET scanner |
DBS testing represents a 10-50x cost reduction compared to traditional biomarker testing approaches.
Proper sample collection is critical for accurate results:
The pivotal study included 337 participants from 7 centers, validating the dried blood spot approach across diverse populations (Huber et al., 2026; PMID:41491101).
| Metric | Result |
|---|---|
| DPS p-tau217 correlation with venous plasma | rS = 0.74, P < 0.001 |
| CSF biomarker positivity prediction (AUC) | 0.864 |
| Disease severity correlation | Progressive increase with severity |
| Self-collection success rate | High concordance with supervised collection |
The approach proved effective in individuals with Down syndrome, showing elevated biomarkers in those with dementia — a population at high risk for Alzheimer's pathology.
| Feature | Dried Blood Spot | CSF Testing | PET Imaging |
|---|---|---|---|
| Invasiveness | Minimal (finger prick) | Moderate (lumbar puncture) | Non-invasive |
| Cost | Low | Moderate | High |
| Accessibility | High (home collection) | Low (clinic required) | Low |
| Scan time | Minutes | Minutes | 30-90 min |
| Infrastructure | Minimal | Moderate | Extensive |
| Biomarkers | Multiple | Multiple | Limited (Aβ, tau) |
Despite promising results, several challenges remain for clinical implementation:
The Blood-Based Biomarkers for Neurodegeneration page provides an overview of this rapidly evolving field. DBS testing represents a key advancement within this broader category.
The AT(N) Biomarker Classification framework provides the organizational system for understanding DBS biomarker profiles.
The Alzheimer's Disease page includes DBS testing as a diagnostic option.
Huber et al. A minimally invasive dried blood spot biomarker test for the detection of Alzheimer's disease pathology (2026). 2026. ↩︎
Kanemaru et al. Japanese validation of blood-based biomarkers for AD (2020). 2020. ↩︎
Park et al. Korean validation of plasma p-tau and NfL (2021). 2021. ↩︎
Li et al. Chinese population reference ranges for blood-based AD biomarkers (2022). 2022. ↩︎
Schindler et al. Blood-based biomarkers in primary care settings (2024). 2024. ↩︎
Cullen et al. DBS for population screening in rural communities (2025). 2025. ↩︎
Mattsson et al. European multicenter validation of dried blood spot p-tau217 (2023). 2023. ↩︎